Mission
To provide drug delivery systems for improved therapy, patient compliance and patent protection Egalet^®.

Egalet a/s concentrates exclusively on research and development, aiming at products and drug delivery processes that are patentable and have broad market appeal. 
 
The corporate strategy focuses on controlling drug development efforts from product formulation to clinical testing, regulatory submissions and manufacturing. As a result, Egalet a/s increasingly focuses its resources on a range of products, in order to secure licensing agreements with major pharmaceutical companies and in return provide significant royalty or profit revenues.

Today, we are licensing the Egalet^® technology to major companies and in 2003 we expect additional development, licensing agreements and product approvals.  We also envision further advances in the development of our product pipeline and the initiation of full-scale manufacturing.

A substantial amount has been invested in product development and patents, and Egalet a/s continues to build a fully integrated pharmaceutical company within the market for controlled release pharmaceuticals which continues to expand, thereby offering new opportunities for Egalet a/s.